ArticleAsian Pacific journal of cancer prevention : APJCP2025
Risk Factors for Oral Mucositis in Pediatric Oncology Patients Undergoing Chemotherapy: A Prospective Cohort.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo verify the risk factors for incidence and severity of oral mucositis (OM) in children and adolescents during anticancer treatment.
methodsA prospective cohort was carried out with 105 patients under 19 years, followed for ten consecutive weeks and submitted to chemotherapy (CT) with or without another treatment modality. Sociodemographic variables were collected using a specific form, with CT regimens obtained from medical records and the oral cavity evaluated by Oral Modified Assessment Guide (OAG). Bivariate comparison tests were used to summarize data and test within- and between-group differences. The longitudinal changes in the participants' condition were modeled by mixed-model regression, using generalized estimating equations.
resultsThe incidence of mild/moderate and severe OM (SOM) ranged from 43.8% to 64.8% and 16.2% to 31.4%, respectively. The sex, age, type of tumor, treatment modality did not statistically influence the severity of OM. The longer the time since the chemotherapy session, the lower the risk of presenting OM and SOM. However, the chances of OM or SOM not occurring at longer intervals between chemotherapy sessions were very low. In most patients who developed OM, the mild/moderate condition persisted for ten weeks and the severe form for three weeks.
conclusionChildren and adolescents with cancer showed oscillations in the severity of OM during antineoplastic treatment and only the time since the last chemotherapy was statistically significant for severity of OM and OAG score.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.